Bogle Investment Management’s United Therapeutics UTHR Stock Holding History

Bogle Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,958	Closed	-$602K	–	265
2020 Q3	$602K	Buy	+5,958	New	+$654K	0.18%	126
2015 Q3	–	Sell	-11,526	Closed	-$2M	–	436
2015 Q2	$2M	Sell	11,526 -90,475	-89%	-$16.3M	0.15%	176
2015 Q1	$17.6M	Buy	102,001 +600	+0.6%	+$91.5K	1.21%	9
2014 Q4	$13.1M	Buy	+101,401	New	+$13.1M	0.87%	19
2014 Q2	–	Sell	-91,044	Closed	-$8.56M	–	385
2014 Q1	$8.56M	Buy	91,044 +63,963	+236%	+$6.54M	0.59%	70
2013 Q4	$3.06M	Sell	27,081 -105,792	-80%	-$9.54M	0.26%	129
2013 Q3	$10.5M	Buy	132,873 +13,930	+12%	+$1.02M	1.06%	7
2013 Q2	$7.83M	Buy	+118,943	New	+$7.66M	0.96%	14

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bogle Investment Management's UTHR Position: Q4 2020 in Review

Bogle Investment Management sold out of United Therapeutics (UTHR) in Q4 2020, closing a stake of 5,958 shares — an estimated $602K sold.

Bogle Investment Management first reported a position in UTHR in Q2 2013 and held it in 8 quarters. The position peaked at $17.6M in Q1 2015. 356 funds tracked by Wall St. Rank hold UTHR as of Q4 2020.

Bogle Investment Management reported no remaining United Therapeutics position as of Q4 2020 after selling out during the quarter.
Bogle Investment Management sold 5,958 United Therapeutics shares in Q4 2020, an estimated $602K.
Bogle Investment Management first reported a position in United Therapeutics in Q2 2013 and held it in 8 quarters.
Bogle Investment Management's United Therapeutics position peaked at $17.6M in Q1 2015.
356 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2020.

Based on Bogle Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.